Ciprofloxacin for pouchitis and E. coli resistance mutations

What is known

• Study of 51 stool samples from 43 UC/IPAA patients (13 ciprofloxacin-treated, 30 untreated) quantified mutations at gyrA 83/87 and parC 80/84. ¹
• Paired samples before and just after starting ciprofloxacin showed increasing mutation rates at gyrA 83/87 and parC 84. ¹
• Fecal and mucosal biopsy mutation rates correlated, suggesting similar mutations in mucosa-associated bacteria. ¹

What is unknown / caveats

• Single small study; treated group was mainly chronic pouchitis on long-term ciprofloxacin (mean 13.9 months)
• Study did not directly test whether ciprofloxacin caused loss of growth inhibition in mutant E. coli strains
• Whether E. coli itself drives pouchitis pathology is uncertain; it was chosen because the mutation-resistance link is well characterized in E. coli.

References

1. Fukushima K, Saito T, Kohyama A, Watanabe K. Increased Quinolone-Resistant Mutations of gyrA and parC Genes after Pouchitis Treatment with Ciprofloxacin. Dig Surg. 2020;37:321-330. PMID: 32182609.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.